Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Drops By 90.9%

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large decline in short interest in April. As of April 30th, there was short interest totaling 399 shares, a decline of 90.9% from the April 15th total of 4,399 shares. Based on an average trading volume of 8,555 shares, the days-to-cover ratio is presently 0.0 days.

enGene Stock Up 22.6%

Shares of ENGNW traded up $0.04 on Wednesday, hitting $0.21. The company’s stock had a trading volume of 75,039 shares, compared to its average volume of 18,892. enGene has a fifty-two week low of $0.11 and a fifty-two week high of $4.20. The company has a 50 day moving average price of $2.17 and a 200 day moving average price of $2.58.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.